We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 15, 2022

Durvalumab With or Without Tremelimumab Plus Chemotherapy as First-Line Therapy for Metastatic NSCLC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
J. Clin. Oncol 2022 Nov 03;[EPub Ahead of Print], ML Johnson, BC Cho, A Luft, J Alatorre-Alexander, SL Geater, K Laktionov, SW Kim, G Ursol, M Hussein, FL Lim, CT Yang, LH Araujo, H Saito, N Reinmuth, X Shi, L Poole, S Peters, EB Garon, T Mok

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading